Inleiding
Geneesmiddelen kunnen gunstige, maar ook schadelijke effecten bij patiënten teweegbrengen. Voordat een geneesmiddel op de markt wordt toegelaten, wordt het onder streng gecontroleerde omstandigheden bij de mens uitgetest. Nieuwe geneesmiddelen die onderzocht worden, worden investigational medicinal product s (IMP’s ) genoemd.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Websites
EMA, Committee for Medicinal Products for Human Use (CHMP), 19 July 2007. Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products. http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002988.pdf.
EM(E)A, ICH topic E11, January 2001. Note for Guidance on Clinical Investigation of Medicinal Products in the Paediatric Population. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002926.pdf.
Good clinical practice guidelines. http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html.
ICH guideline M3(R2), December 2009. ICH guideline M3(R2) on non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals, step 5. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002720.pdf.
ICH Richtlijnen voor ontwikkeling van geneesmiddelen. http://www.ich.org/products/guidelines.
MedDRA Maintenance and Support Services Organization. http://www.meddramsso.com/.
US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), July 2005. Guidance for Industry. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. http://www.fda.gov/downloads/Drugs/Guidances/UCM078932.pdf.
US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), January 2006. Guidance for Industry, investigators and reviewers. Exploratory IND studies. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM078933.pdf.
What is a serious adverse event? http://www.fda.gov/safety/medwatch/howtoreport/ucm053087.htm.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Copyright information
© 2014 Bohn Stafleu van Loghum
About this chapter
Cite this chapter
Van Bortel, L., Vanmolkot, F., Van Lancker, G. (2014). Exploratory clinical development. In: Out, H., van Meurs, P., van Olden, R. (eds) Handboek farmaceutische geneeskunde. Bohn Stafleu van Loghum, Houten. https://doi.org/10.1007/978-90-368-0265-9_2
Download citation
DOI: https://doi.org/10.1007/978-90-368-0265-9_2
Published:
Publisher Name: Bohn Stafleu van Loghum, Houten
Print ISBN: 978-90-368-0264-2
Online ISBN: 978-90-368-0265-9
eBook Packages: Dutch language eBook collection